302 related articles for article (PubMed ID: 31552601)
21. Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Rafia R; Scope A; Harnan S; Stevens JW; Stevenson M; Lobo A
Pharmacoeconomics; 2016 Dec; 34(12):1241-1253. PubMed ID: 27480631
[TBL] [Abstract][Full Text] [Related]
22. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
[TBL] [Abstract][Full Text] [Related]
23. Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.
Favale A; Onali S; Caprioli F; Pugliese D; Armuzzi A; Macaluso FS; Orlando A; Viola A; Fries W; Rispo A; Castiglione F; Mocci G; Chicco F; Usai P; Calabrese E; Biancone L; Monteleone G; Fantini MC;
Inflamm Bowel Dis; 2019 Oct; 25(11):1805-1812. PubMed ID: 30931477
[TBL] [Abstract][Full Text] [Related]
24. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.
Stawowczyk E; Kawalec P; Pilc A
Pharmacotherapy; 2016 May; 36(5):472-81. PubMed ID: 27007213
[TBL] [Abstract][Full Text] [Related]
25. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M
PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175
[TBL] [Abstract][Full Text] [Related]
26. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model.
Scott FI; Shah Y; Lasch K; Luo M; Lewis JD
Inflamm Bowel Dis; 2018 Jan; 24(2):286-295. PubMed ID: 29361100
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety of vedolizumab and infliximab in biologic-naïve patients with moderate-to-severe ulcerative colitis: A multicenter, retrospective cohort study.
Meng RP; Huang BB; Wei YL; Lyu L; Yang H; Liu C; Zhou HL; Liao XP; Zhou JY; Xie X
J Dig Dis; 2024 Apr; 25(4):230-237. PubMed ID: 38764418
[TBL] [Abstract][Full Text] [Related]
28. A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis.
Stawowczyk E; Kawalec P
Pharmacoeconomics; 2018 Apr; 36(4):419-434. PubMed ID: 29260508
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective.
Goeree R; Chiva-Razavi S; Gunda P; Jain M; Jugl SM
J Med Econ; 2019 Jan; 22(1):45-52. PubMed ID: 30346844
[TBL] [Abstract][Full Text] [Related]
30. The biologics of ulcerative colitis.
Macaluso FS; Renna S; Orlando A; Cottone M
Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557
[TBL] [Abstract][Full Text] [Related]
31. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of abrocitinib compared with standard of care in adult moderate-to-severe atopic dermatitis in Japan.
Tanaka A; Yuasa A; Kamei K; Nagano M; Murofushi T; Bjerke A; Nakamura K; Ikeda S
J Dermatol; 2024 Jun; 51(6):759-771. PubMed ID: 38650307
[TBL] [Abstract][Full Text] [Related]
33. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.
Gherardi A; Roze S; Kuijvenhoven J; Ghatnekar O; Yip Sonderegger YL
J Med Econ; 2018 Sep; 21(9):869-877. PubMed ID: 29857775
[TBL] [Abstract][Full Text] [Related]
34. Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.
Emery P; Van Keep M; Beard S; Graham C; Miles L; Jugl SM; Gunda P; Halliday A; Marzo-Ortega H
Pharmacoeconomics; 2018 Aug; 36(8):1015-1027. PubMed ID: 29797186
[TBL] [Abstract][Full Text] [Related]
35. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.
Thorlund K; Druyts E; Mills EJ; Fedorak RN; Marshall JK
J Crohns Colitis; 2014 Jul; 8(7):571-81. PubMed ID: 24491514
[TBL] [Abstract][Full Text] [Related]
36. Real-world effectiveness of ustekinumab and vedolizumab in TNF-exposed pediatric patients with ulcerative colitis.
Patel PV; Zhang A; Bhasuran B; Ravindranath VG; Heyman MB; Verstraete SG; Butte AJ; Rosen MJ; Rudrapatna VA;
J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1126-1134. PubMed ID: 38482890
[TBL] [Abstract][Full Text] [Related]
37. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
Dignass AU; Siegmund B; Goertz R; Schneidewind G; Fanter L
Scand J Gastroenterol; 2019 Feb; 54(2):178-187. PubMed ID: 30735443
[TBL] [Abstract][Full Text] [Related]
38. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
39. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.
Stawowczyk E; Kawalec P; Pilc A
Eur J Clin Pharmacol; 2016 Nov; 72(11):1319-1325. PubMed ID: 27497991
[TBL] [Abstract][Full Text] [Related]
40. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.
Yu AP; Johnson S; Wang ST; Atanasov P; Tang J; Wu E; Chao J; Mulani PM
Pharmacoeconomics; 2009; 27(7):609-21. PubMed ID: 19663531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
